Current Clinical Research Studies
Current Studies

Janssen is committed to transforming the way lung cancer is researched and treated. That is why we are always learning, innovating, and advancing investigational medicines with the goal of redefining what is possible in the treatment of non-small-cell lung cancer (NSCLC).

We are currently conducting the following research studies on investigational medicines that aim to specifically target EGFR-positive NSCLC.

The CHRYSALIS Study is evaluating the safety and effectiveness of an investigational medication for different groups of people with NSCLC. Participants in the groups that are currently enrolling need to have NSCLC with either a primary gene mutation known as the MET Exon 14 skipping mutation or NSCLC with types known as adenocarcinoma or squamous cell carcinoma without certain gene mutations (EGFR and ALK) on tumor testing. Learn more about the CHRYSALIS research study here.

The CHRYSALIS 2 Study is evaluating the safety and effectiveness of an investigational medication in combination with another investigational medication for different groups of people with advanced NSCLC. Learn more about the Chrysalis 2 research study here.

The MARIPOSA Study is evaluating the safety and effectiveness of one investigational medication or a combination of two investigational medications. Participants in this study need to have one of two relatively common EGFR mutations: Exon 19 deletion or Exon 21 L858R substitution.

The MARIPOSA 2 Study is evaluating the safety and effectiveness of a combination of two investigational medications in addition to approved chemotherapy. Participants in this study need to have one of two relatively common EGFR mutations: Exon 19 deletion or Exon 21 L858R substitution. Learn more about the MARIPOSA 2 research study here.

The PAPILLON Study is evaluating the safety and effectiveness of an investigational medication in combination with chemotherapy. Participants in this study need to have a rare form of EGFR mutation called an Exon 20 insertion. Learn more about the PAPILLON research study here.

New studies will be added as they become available. Check back here frequently for updates.

If you are not sure which research study is for you, take this short survey to find out.

If you want to learn how biomarker testing can determine mutation types, visit this page.

This website includes information about clinical research studies in the United States. To see a list of participating countries please visit this page.

Study Locations

The map below shows the locations where we currently have study clinics supporting our different NSCLC clinical research studies. If there’s no study clinic currently located in your area, you still have the option to answer a brief questionnaire here to see if you may qualify and save your information so we can reach out to you as new study clinics open up in your area.

New studies and study clinics may be added periodically, so please come back and check this page as frequently as you like.

Participating Countries

Below is a list of currently participating countries for the Chrysalis, Chrysalis 2, Mariposa, Mariposa 2, and Papillon clinical research studies. For more information, please visit ClinicalTrials.gov.

north america

Canada

Puerto Rico

United States

Europe

Belgium

Bulgaria

Czech Republic

Denmark

France

Germany

Hungary

Italy

Netherlands

Poland

Portugal

Russia

Spain

Sweden

Turkey

Ukraine

United Kingdom

Asia & Pacific

Australia

China

Hong Kong

India

Japan

Korea

Malaysia

Taiwan

Thailand

South / Latin America

Argentina

Brazil

Mexico

Middle East

Israel

If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path. 

The more we learn, the farther we can go.